BioCentury | Mar 23, 2018
Clinical News

Anthera discontinues development of Sollpura

Anthera Pharmaceuticals Inc. (NASDAQ:ANTH) discontinued development of Sollpura liprotamase (LY3031642) after the candidate missed the primary endpoint in the Phase III RESULT trial to treat exocrine pancreatic insufficiency due to cystic fibrosis. The company said...
BioCentury | Sep 14, 2017
Targets & Mechanisms

Platelets YAP at cancer

While elevated platelet levels often signify an underlying malignancy, the molecular mechanisms linking the two are not well understood. Now, a team from MD Anderson has shown a well-known, but barely exploited signaling pathway mediates...
BioCentury | Sep 13, 2017
Distillery Therapeutics


INDICATION: Ovarian cancer; colorectal cancer Cell culture and mouse studies suggest inhibiting YAP1 could help treat platelet-enhanced metastases of ovarian and colorectal cancers. In human metastatic ovarian or colorectal cancer cell lines co-cultured with human...
BioCentury | Nov 5, 2015
Distillery Therapeutics

Therapeutics: Calcineurin; calcineurin A γ (PPP3CC; CNA3)

...contraception. In normal male mice, PPP3CC knockout decreased sperm motility and fertility compared with normal PPP3CC...
...testing sperm-specific calcineurin inhibitors in models of male fertility. TARGET/MARKER/PATHWAY: Calcineurin; calcineurin A γ (PPP3CC; CNA3...
BioCentury | Aug 14, 2014
Distillery Techniques

Technology: Markers

Approach Summary Licensing status Publication and contact information Markers Copy number alteration (CNA) burden to predict prostate cancer recurrence Studies in patient samples suggest CNA burden could help predict prostate cancer recurrence and metastasis. In...
BioCentury | Jan 7, 2013
Company News

Open Monoclonal Technology, J&J deal

On Dec. 21, 2012, Open Monoclonal Technology said it and the CNA Development LLC affiliate of Janssen Pharmaceuticals Inc. partnered to generate antibodies against undisclosed targets from Janssen. Open Monoclonal Technology will use its OmniRat...
BioCentury | Jul 29, 2010
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Chronic myelogenous leukemia (CML); acute lymphocytic leukemia (ALL) Calcineurin Aa (PPP3CA; CNA1); nuclear factor of activated T cells cytoplasmic calcineurin-dependent 1 (NFATc1) In vitro and...
BioCentury | Oct 19, 2009
Clinical News

Creon pancrelipase: Phase III data

Data from a double-blind, crossover Phase III trial in 32 patients showed that Creon met the primary endpoint of significantly greater CFA vs. placebo (88.6% vs. 49.6%, p<0.001). Creon also met the secondary endpoint of...
BioCentury | May 28, 2009
Targets & Mechanisms

New angiogenesis targets

An international collaboration among researchers at the Karolinska Institute , Discovery Genomics Inc. and AngioGenetics AB has produced a set of previously unknown and potentially druggable targets in angiogenesis along with several matching antiangiogenic compounds. 1...
BioCentury | Apr 9, 2007
Clinical News

Zentase: Phase III data

In a double-blind, U.S. Phase III trial, Zentase met the primary endpoint of a significant increase in the coefficient of fat absorption (CFA) vs. placebo. The mean CFA was 88.3% in the Zentase arm and...
Items per page:
1 - 10 of 10